On April 11, 2022 Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, reported that an oral presentation and poster presentation for RBN-2397, the Company’s lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 taking place in New Orleans, Louisiana (Press release, Ribon Therapeutics, APR 11, 2022, View Source [SID1234611960]). RBN-2397 is a small molecule inhibitor of PARP7 being evaluated in multiple clinical trials for the treatment of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present additional clinical and preclinical data from our RBN-2397 program that provides further evidence that PARP7 inhibition induces a tumor-specific immune response by activating Type I interferon signaling pathways," said Prakash Raman, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. "Combining RBN-2397 with immune checkpoint inhibitors is anticipated to further potentiate the immune response in a variety of tumor types, and we look forward to evaluating this in our ongoing Phase 1b/2 trial of RBN-2397 in combination with pembrolizumab in patients with squamous cell carcinoma of the lung."

Details for the AACR (Free AACR Whitepaper) Annual Meeting 2022 presentations are as follow:

Poster presentation:

Abstract Title: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors

Abstract ID: 1836

Session Title: Mechanism of Drug Action 1

Date & Time: Monday, April 11, 2022, from 1:30 p.m. to 5:00 p.m. CDT

Summary:

RBN-2397 induces tumor-specific interferon pathway activation and increases immune cell infiltration into patient tumors being evaluated in a Phase 1 trial of RBN-2397 as a monotherapy, providing evidence for the induction of an adaptive immune response.
This data confirms the tumor-intrinsic, immunomodulatory mechanism of action of RBN-2397, and supports additional studies of RBN-2397 in combination with immune checkpoint inhibitors.
Oral presentation:

Abstract Title: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models

Abstract ID: 2154

Session Title: Emerging New Anticancer Agents

Date & Time: Monday, April 11, 2022, from 2:30 p.m. to 4:30 p.m. CDT

Summary:

In preclinical cancer models, RBN-2397 leads to tumor regression by activation of Type I interferon signaling resulting in antitumor immunity, as well as tumor intrinsic mechanisms including cellular senescence, interference with autophagy, and changes in tumor cell metabolism
The data demonstrate that both tumor intrinsic and immune system mediated effects of RBN-2397 contribute to its antitumor activity.
The AACR (Free AACR Whitepaper) presentations are available on its corporate website via the following link: View Source

About RBN-2397

RBN-2397 is an orally available small molecule inhibitor of PARP7 being developed for the treatment cancer. PARP7 is upregulated in response to cellular stress, including genomic instability in cancers, and acts as a brake on the cellular stress response by negatively regulating the Type I interferon response. By inhibiting PARP7 in tumor cells, RBN-2397 has been shown to directly inhibit cellular proliferation and restore interferon signaling to stimulate an innate and adaptive antitumor immune response. RBN-2397 is currently in a Phase 1 clinical trial as a monotherapy in patients with advanced solid tumors and in a Phase 1b/2 clinical trial in combination with pembrolizumab. PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung, or SCCL, which represents approximately 30% of all non-small cell lung cancers.